SCHEMBL1923967

SCHEMBL1923967

NC(=O)c1[nH]cc(CCC(=O)O)c1-c1ccc(NC(=O)Nc2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.51
MAPT P10636 1/20 0.51
HTT P42858 1/20 0.51
RAB9A P51151 1/20 0.51
KMT2A Q03164 1/20 0.51
KDR P35968 11/20 0.51
PDGFRB P09619 3/20 0.51
KCNMA1 Q12791 1/20 0.48
AURKB Q96GD4 3/20 0.46
KIT P10721 3/20 0.46
FLT3 P36888 3/20 0.46
NTRK1 P04629 2/20 0.46
NTRK2 Q16620 2/20 0.46
AURKA O14965 2/20 0.46
GOT1 P17174 1/20 0.46
PLK4 O00444 1/20 0.46
ROCK2 O75116 1/20 0.46
CHEK2 O96017 1/20 0.46
EGFR P00533 1/20 0.46
LCK P06239 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1925334 0.90 EPHX2 (0.48) MEN1MAPTKMT2AKDRGOT1
SCHEMBL1925039 0.88 RIPK1 (0.44) MEN1MAPTHTTRAB9AKMT2A
SCHEMBL1925038 0.88 ROCK2 (0.46) MEN1MAPTRAB9AKMT2AKDR
SCHEMBL1925178 0.86 KDR (0.49) KDRPDGFRBAURKBKITFLT3
SCHEMBL1925429 0.86 RIPK1 (0.46) MEN1MAPTKMT2AKDRPDGFRB
SCHEMBL1924620 0.86 CSF1R (0.53) MEN1MAPTKMT2AKDRPDGFRB
SCHEMBL1924020 0.85 CDK8 (0.43) KDRAURKBKITFLT3NTRK1
SCHEMBL1924893 0.84 KDR (0.51) KDRCDK8RIPK1
SCHEMBL1924795 0.84 CDK8 (0.44) KDRPDGFRBRETCDK8EPHX2
SCHEMBL1923760 0.84 MEN1 (0.56) MEN1MAPTHTTRAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856043-B1 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER AVENTIS PHARMA SA (FR) 2011-06-08 EP claimed